Tags

Type your tag names separated by a space and hit enter

[Dysimmune neuropathies: current diagnosis and therapy].
Rev Prat. 2008 Nov 15; 58(17):1887-9, 1892-4.RP

Abstract

Dysimmune neuropathies encompass an acute form, Guillain-Barré syndrome (GBS), and mainly 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy, and polyneuropathy associated with anti-MAG (myelin-associated-glycoprotein) IgM monoclonal gammopathy. Recent concepts have concerned both incidence and mortality rates, and better scoring system for predict outcome in GBS, but new therapeutical strategy is needed for the so-called "benign" forms and for relapsing forms after first-line IVIg therapy. In chronic forms, criteria for diagnosis and guidelines for management have been edited in the recent years, together with recommendations for outcome measures. However, there is still a need for knowing the better outcome measures, and to elaborate new trials, mainly focusing on the long-term management of the patients.

Authors+Show Affiliations

Centre de référence maladies neuromusculaires rares Paris-Est, France. jean-marc.leger@psl.aphp.frNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

19157204

Citation

Léger, Jean-Marc, et al. "[Dysimmune Neuropathies: Current Diagnosis and Therapy]." La Revue Du Praticien, vol. 58, no. 17, 2008, pp. 1887-9, 1892-4.
Léger JM, Larue S, Dashi F. [Dysimmune neuropathies: current diagnosis and therapy]. Rev Prat. 2008;58(17):1887-9, 1892-4.
Léger, J. M., Larue, S., & Dashi, F. (2008). [Dysimmune neuropathies: current diagnosis and therapy]. La Revue Du Praticien, 58(17), 1887-9, 1892-4.
Léger JM, Larue S, Dashi F. [Dysimmune Neuropathies: Current Diagnosis and Therapy]. Rev Prat. 2008 Nov 15;58(17):1887-9, 1892-4. PubMed PMID: 19157204.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Dysimmune neuropathies: current diagnosis and therapy]. AU - Léger,Jean-Marc, AU - Larue,Sandrine, AU - Dashi,Florian, PY - 2009/1/23/entrez PY - 2009/1/23/pubmed PY - 2009/2/12/medline SP - 1887-9, 1892-4 JF - La Revue du praticien JO - Rev Prat VL - 58 IS - 17 N2 - Dysimmune neuropathies encompass an acute form, Guillain-Barré syndrome (GBS), and mainly 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy, and polyneuropathy associated with anti-MAG (myelin-associated-glycoprotein) IgM monoclonal gammopathy. Recent concepts have concerned both incidence and mortality rates, and better scoring system for predict outcome in GBS, but new therapeutical strategy is needed for the so-called "benign" forms and for relapsing forms after first-line IVIg therapy. In chronic forms, criteria for diagnosis and guidelines for management have been edited in the recent years, together with recommendations for outcome measures. However, there is still a need for knowing the better outcome measures, and to elaborate new trials, mainly focusing on the long-term management of the patients. SN - 0035-2640 UR - https://www.unboundmedicine.com/medline/citation/19157204/[Dysimmune_neuropathies:_current_diagnosis_and_therapy]_ DB - PRIME DP - Unbound Medicine ER -